1. Medtech Insight
  2. >>Device Area
  3. >>Cardiology

ESC Roundup: Questions Raised About Remote Monitoring Benefits And Preventative ICDs; Medtronic Upgrades CRT Algorithms

 
• By Reed Miller

This year's European Society of Cardiology Congress in Rome featured presentations of data from several major clinical trials that may cause cardiologists to rethink some of their established device therapies, including ICDs for the primary prevention of sudden cardiac death and remote monitoring of implantable devices in heart-failure patients.

Heart
• Source: Shutterstock

Remote monitoring of cardiac resynchronization defibrillators (CRT-D) did not reduce mortality of heart failure patients beyond the benefits of regular office-based care in the MORE CARE study. However, the trial results also indicate that remote monitoring can reduce the overall costs of treating these patients without compromising patient safety by reducing the number of in-office visits.

Giuseppe Boriani of the University of Modena and Reggio Emilia in Italy presented data from 865 patients in MORE CARE...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiology

Abbott’s Navitor TAVR Wins CE Mark Expansion, New Guidelines Allow Treatment For Younger Patients

 
• By Marion Webb

Abbott’s Navitor TAVR system is now CE-marked for low to intermediate risk patients, based on positive data from the Vintage trial. The EACTS guidelines for TAVR lowered the recommended age for patients with severe aortic stenosis to 70 years and older, which opens up treatment for younger patients.

Tariffs In Focus: Projections From 4 Medtech Giants (Q1 Vs Q2)

 
• By Marion Webb, Shubham Singh, and Nancy Pham

Roche Diagnostics, Intuitive Surgical, Abbott and Edwards Lifesciences all acknowledge tariff headwinds, but stress preparedness, resilience and mitigation. Below is look at how management framed the impact in Q1 vs Q2 earnings calls.

A Decade Of Breakthrough Devices: Cardiac And Orthopedic Products Dominate FDA Designations

 
• By Brian Bossetta and Elizabeth Orr

The US FDA has provided an update on its breakthrough devices program, now 10 years running. Cardiac, orthopedic, and neurological devices have received the most designations, while only one has been awarded to an obstetrics/gynecology product.

Medtronic Posts Solid First-Quarter, Adds Board Members As Elliott Takes Stake

 
• By Marion Webb

Medtronic beat first-quarter revenue and EPS estimates, raised guidance, and added two board members and special committees as Elliott takes a stake.

More from Device Area

Highridge Medical CEO Whitney On Accelus Buys And Spine Strategy

 
• By Ashley Yeo

After divesting bone healing products in mid-year, Highridge Medical doubled down on its spine capabilities with a triple purchase of technologies from Accelus, bringing access to “Adaptive Geometry.” CEO Rebecca Whitney explained Highridge’s strategy.

Salient Bio Raises £2.35M For March 2026 Rollout Of At-Home IBD Microbiome Test

 
• By Natasha Barrow

Salient's inflammatory bowel disease test, built on the start-up’s Signal platform, is planned to launch in March 2026. The company leverages rich data from existing wellness tests to develop signatures, focusing on conditions that are often misdiagnosed and disproportionately affect women.

Abbott’s Navitor TAVR Wins CE Mark Expansion, New Guidelines Allow Treatment For Younger Patients

 
• By Marion Webb

Abbott’s Navitor TAVR system is now CE-marked for low to intermediate risk patients, based on positive data from the Vintage trial. The EACTS guidelines for TAVR lowered the recommended age for patients with severe aortic stenosis to 70 years and older, which opens up treatment for younger patients.